Showing 5221-5230 of 5644 results for "".
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging-2/2476749/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a Medscape
- Nidek Launches LPM Low Power Mode for YLC-500 Vixihttps://modernod.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/Nidek has announced the launch of LPM optional software, a low power mode for the YLC-500 Vixi laser photocoagulator. LPM delivers a therapeutic effect to the retina by decreasing the laser power during photocoagulati
- Clerio Vision Acquires Manufacturer of Extreme H2O Contact Lenseshttps://modernod.com/news/clerio-vision-acquires-manufacturer-of-extreme-h2o-contact-lenses/2476732/Clerio Vision announced that it has acquired Hydrogel Vision Corporation (HVC), a manufacturer and distributor of contact lenses. Terms of the deal were not disclosed. HVC, founded in 2002, is best known for its Extreme H2O product line and its multiple differentiated offerings that
- US Scraps Proposal to Curb Drug Rebates Paid to Pharmacy Benefit Managershttps://modernod.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/The US government pulled the plug on plans designed to reduce drug prices by limiting rebates paid by drugmakers to pharmacy benefit managers (PBMs). White House spokesman Judd Deere said on Thursday that “based on careful analysis and thorough consideration, the President has decided to wi
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- SparingVision Awarded €2.5 Million at EIC Accelerator Programhttps://modernod.com/news/sparingvision-awarded-e2-5-million-at-eic-accelerator-program/2476715/SparingVision announced that it has been awarded non-dilutive funding of €2.5 million to fund research into retinitis pigmentosa therapies. SparingVision submitted a winning proposal for the European EIC Accelerator (SME instrument phase 2) program. The funding will help speed up SparingVi
- Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/Horizon Therapeutics announced that it has submitted a biologics license application (BLA) to the FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has breakthrough therapy, orphan drug and fast track designations from the FDA. H